GlobeNewswire·Nov 12, 2026, 7:30 AM ET

Altimmune Announces Third Quarter 2026 Financial Results and Business Update

Altimmune reported $480 million in cash, cash equivalents, and investments as of September 30, 2026.
The global PERFORMA Phase 3 trial for MASH is progressing as planned with a 52-week topline readout anticipated in 2029.
Positive RECLAIM Phase 2 data for AUD was highlighted in a late-breaking oral presentation at AASLD The Liver Meeting 2026.
An End-of-Phase 2 meeting with the FDA for the AUD program is scheduled for December 2026 to discuss the Phase 3 registrational program.
Enrollment is complete in the RESTORE Phase 2 trial for ALD, with topline data expected in the second half of 2027.
Pemvidutide received Breakthrough Therapy Designation from the FDA for MASH based on 24-week IMPACT Phase 2b data.
Research and development expenses were $27.0 million for the three months ended September 30, 2026, driven by the PERFORMA MASH trial and RESTORE ALD trial.
Net loss for the three months ended September 30, 2026, was $31.6 million, or $0.15 per share, compared to $19.0 million in the same period in 2025.
Peter Greenleaf and Alex Howarth were appointed to the Board of Directors in October 2026 to support strategic evolution.
Altimmune relocated its corporate headquarters to Morristown, New Jersey, in November 2026.